A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

NCT06155396 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

116

Enrollment

INDUSTRY

Sponsor class

Conditions

Cervical Cancer

Interventions

DRUG: Disitamab Vedotin
DRUG: Zimberelimab

Sponsor

RemeGen Co., Ltd.